XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note A - Description of Business, Basis of Presentation and Significant Transactions - Consideration Paid and Purchase Price Allocation for the Acquisition of Arimoclomol (Details) - Arimoclomol Purchase Agreement [Member] - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
May 15, 2022
Sep. 30, 2022
Sep. 30, 2022
Cash $ 12,800    
Assumed reserve liability 5,200 $ 6,300 $ 6,300
Total consideration 18,000    
Total consideration 18,000    
Direct transaction costs associated with the acquisition (1) [1] 1,290    
Total purchase price to be allocated 19,290    
Property and equipment, inventory and assembled workforce acquired 1,627    
Total allocated purchase price 19,290    
In Process Research and Development [Member]      
IPR&D (2) [2] $ 17,663    
[1] As a result of the asset acquisition accounting, the transaction costs associated with the acquisition should be included in the costs of the assets acquired and allocated amongst qualifying assets using the relative fair value basis. The transaction costs primarily included financial advisor fees, legal expenses and auditor expenses.
[2] The primary asset acquired, the IPR&D asset, was expensed and the allocated transaction related costs were included with and expensed with this asset.